Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6275887 | 0.69 | CYP4F2 (0.45) | NPC1RAB9ASMN1; SMN2CA2CYP1A2 | |
| SCHEMBL5219842 | 0.65 | KDM4E (0.40) | NPC1RAB9ASMN1; SMN2CA12CA1 | |
| SCHEMBL5221511 | 0.65 | ALDH1A1 (0.39) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL9039147 | 0.64 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2RECQLMAPK10 | |
| SCHEMBL9126131 | 0.64 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2RECQLMAPK10 | |
| SCHEMBL309368 | 0.64 | KDM4E (0.41) | NPC1RAB9ASMN1; SMN2CA12CA1 | |
| SCHEMBL9038215 | 0.62 | HPGD (0.53) | NPC1RAB9ASMN1; SMN2RECQLMAPK10 | |
| SCHEMBL7353327 | 0.61 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2RECQLMAPK10 | |
| SCHEMBL28565106 | 0.61 | SMN1; SMN2 (0.42) | NPC1RAB9ASMN1; SMN2RECQLMAPK10 | |
| SCHEMBL24376040 | 0.60 | ALDH1A1 (0.46) | RAB9ASMN1; SMN2RECQLMAPK10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | NPC1 1554/4885RAB9A 2403/4885SMN1; SMN2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.